The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS).
Boissinot
Marjorie
M
Garand
Richard
R
Hamidou
Mohamed
M
Hermouet
Sylvie
S
D000368:Aged; D000369:Aged, 80 and over; D019943:Amino Acid Substitution; D000753:Anemia, Refractory / Q000145:classification / Q000201:enzymology / Q000235:genetics*; D000756:Anemia, Sideroblastic / Q000145:classification / Q000201:enzymology / Q000235:genetics*; D017931:DNA Primers; D005260:Female; D006801:Humans; D053614:Janus Kinase 2; D008297:Male; D009154:Mutation; D016133:Polymerase Chain Reaction; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D013920:Thrombocythemia, Essential / Q000145:classification / Q000201:enzymology / Q000235:genetics*
D017931:DNA Primers; D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2